Summary: Neurable will license its non-invasive EEG-and-AI brain-computer interface stack to consumer electronics makers for headphones, hats, glasses, and headbands. CEO Ramses Alcaide frames the goal as making cognitive sensing as widespread as heart-rate sensors, with health, productivity, and gaming as target categories. Existing HyperX and iMotions deployments show early demand, while neural-data privacy and consent remain central adoption conditions.
TechCrunch reported on April 28, 2026 that Neurable, a startup working on brain-computer interfaces (BCI), will put its non-invasive “mind-reading” technology up for license to consumer electronics makers. The stack: EEG sensors paired with signal processing scan brain activity, and AI then analyzes the signals to gauge cognitive performance. An OEM can build the complete package into headphones, hats, glasses, and headbands — and keep product design, user experience, and distribution entirely in its own hands.
When the announcement landed is part of the story. Neurable raised a $35 million Series A in December 2025 (MobiHealthNews covered it) for the stated purpose of scaling commercialization, and this licensing announcement spells out where that money goes: instead of shipping consumer devices under its own name, the company wants to sit inside everyone else’s wearables as the standard component supplier.
BCI Without the Scalpel
Ask most people what BCI brings to mind and the answer is Neuralink: opening the skull, implanting chips, running human trials. That route has drawn serious investor backing — Neuralink collected a $650 million Series E in June 2025. Neurable operates at the opposite end: fully non-invasive, with EEG sensors on the scalp picking up brainwaves and signal processing plus AI models handling the interpretation. Implanted electrodes still win on precision, but no surgical risk, all-day wearability, and mass manufacturability are just the qualities consumer electronics companies look for — the ones that could turn neural monitoring into “a heart-rate strap for your head.”
Licensing Play: Brain Sensing as a Standard Part
CEO Ramses Alcaide can fit the goal into a single line: “let’s make this as ubiquitous as heart rate sensors on your wrist.” In his telling, the industry has reached an inflection point, and “a real business model in neuro-technology that is scalable” has appeared for the first time.
The play itself is component licensing. Three application categories are in scope: health and athletic products, productivity tools, and gaming. Hardware and brand stay with the OEM; the sensing and AI interpretation layer stays with Neurable. For a device maker, that means “cognitive state” becomes a new sensing dimension on a headphone or headband without assembling an in-house neuroscience team — the way heart rate and blood oxygen found their way into wearables over the past decade.
Risk gets spread as well. A component supplier never has to predict which form factor wins — headphones, headbands, glasses, or hats — since it ships inside all of them. And each OEM category that takes on the stack brings another stream of training signal and distribution, sparing Neurable any capital of its own for retail. That is the structural case for why licensing, not a first-party device, is the plausible route to ubiquity for a neurotech company at this stage.
From Esports Headsets to Behavior Research
Two deployments are already running. The first is HyperX, HP’s gaming brand: the brain-tracking gaming headset the two companies built together is pitched as helping gamers “level up their game play by optimizing focus and performance,” and it came away with top honors at CES 2026. The second is iMotions, a software platform for human behavior research, which has folded the Neurable headset into its research workflows so academic teams can bring EEG data straight into behavioral experiments. On new partners, Alcaide named no names — only that the company is expanding across multiple domains.
Where the Privacy Line Sits for Neural Data
Brainwaves are a more sensitive signal than heartbeats, so the privacy question has to be answered rather than sidestepped. Neurable’s answer: user data is encrypted and anonymized, the company works to HIPAA standards, and its safeguards go “above and beyond where a lot of startups would be at our stage.” AI training on neural data happens only with the user’s consent and only when tied to specific experiments — to quote Alcaide, “We are not collecting the data, just training on it willy-nilly.”
Whether that commitment proves durable as an institution is still an open question, but the direction is unmistakable. AI is stepping out of the clinic and the lab into day-to-day health monitoring, a range that spans Oxford’s CT heart-failure prediction through the brainwave sensor worn on the head; along that road, whether a product can be trusted will weigh on its data governance as heavily as on its algorithm. Heart-rate sensors needed a decade to become ubiquitous; for EEG sensing to retrace that path, privacy engineering is the first hurdle to clear.